Semaglutide was associated with more than twice the risk for nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitors, although the absolute risk “remained low,” according to a study published in JAMA Ophthalmology.
“Although [semaglutide is] effective for glycemic control, weight loss and cardiovascular risk reduction, nonarteritic anterior ischemic optic neuropathy (NAION) has emerged as a serious rare adverse event,” Kent Heberer, PhD, data scientist at the U.S. Department of Veterans Affairs, and colleagues wrote. “Studies show